CN107325188B - 猪血清蛋白融合猪圆环病毒Cap2蛋白的CHO细胞株的构建方法及其应用 - Google Patents
猪血清蛋白融合猪圆环病毒Cap2蛋白的CHO细胞株的构建方法及其应用 Download PDFInfo
- Publication number
- CN107325188B CN107325188B CN201710603507.XA CN201710603507A CN107325188B CN 107325188 B CN107325188 B CN 107325188B CN 201710603507 A CN201710603507 A CN 201710603507A CN 107325188 B CN107325188 B CN 107325188B
- Authority
- CN
- China
- Prior art keywords
- protein
- recombinant
- fusion protein
- pigpsa
- cap2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004978 chinese hamster ovary cell Anatomy 0.000 title claims abstract description 24
- 241000202347 Porcine circovirus Species 0.000 title claims abstract description 19
- 101150014715 CAP2 gene Proteins 0.000 title claims description 22
- 108010017384 Blood Proteins Proteins 0.000 title claims description 9
- 102000004506 Blood Proteins Human genes 0.000 title claims description 8
- 101100260872 Mus musculus Tmprss4 gene Proteins 0.000 title description 16
- 238000010276 construction Methods 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 73
- 210000004027 cell Anatomy 0.000 claims abstract description 68
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 53
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 42
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 42
- 230000014509 gene expression Effects 0.000 claims abstract description 38
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 27
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 27
- 229960005486 vaccine Drugs 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 8
- 230000003248 secreting effect Effects 0.000 claims abstract description 6
- 239000002158 endotoxin Substances 0.000 claims abstract description 5
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 4
- 239000013598 vector Substances 0.000 claims description 45
- 150000007523 nucleic acids Chemical class 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 108020004414 DNA Proteins 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 238000000855 fermentation Methods 0.000 claims description 11
- 230000004151 fermentation Effects 0.000 claims description 11
- 102000053602 DNA Human genes 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 9
- 239000002299 complementary DNA Substances 0.000 claims description 8
- 230000004927 fusion Effects 0.000 claims description 8
- 239000012620 biological material Substances 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 6
- 101100326803 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fac-2 gene Proteins 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 238000001962 electrophoresis Methods 0.000 claims description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 5
- 239000013613 expression plasmid Substances 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- 108020004511 Recombinant DNA Proteins 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000013600 plasmid vector Substances 0.000 claims description 3
- 235000019750 Crude protein Nutrition 0.000 claims description 2
- 238000013373 clone screening Methods 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims description 2
- 238000001638 lipofection Methods 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 238000007747 plating Methods 0.000 claims description 2
- 238000001742 protein purification Methods 0.000 claims description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims 1
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 claims 1
- 230000012743 protein tagging Effects 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 16
- 125000000539 amino acid group Chemical group 0.000 abstract description 14
- 238000012217 deletion Methods 0.000 abstract description 14
- 230000037430 deletion Effects 0.000 abstract description 14
- 238000006467 substitution reaction Methods 0.000 abstract description 14
- 238000000746 purification Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 238000010353 genetic engineering Methods 0.000 abstract description 4
- 230000034994 death Effects 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 230000002829 reductive effect Effects 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 description 20
- 102000040430 polynucleotide Human genes 0.000 description 19
- 108091033319 polynucleotide Proteins 0.000 description 19
- 239000002157 polynucleotide Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 14
- 241000282887 Suidae Species 0.000 description 13
- 241000282898 Sus scrofa Species 0.000 description 13
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 230000010076 replication Effects 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 230000003053 immunization Effects 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241001673669 Porcine circovirus 2 Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 6
- 241001661006 Pepper cryptic virus 2 Species 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 4
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 4
- 102100024407 Jouberin Human genes 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 229940031626 subunit vaccine Drugs 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 241001533384 Circovirus Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241001504982 Pepper cryptic virus 1 Species 0.000 description 3
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 3
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000725585 Chicken anemia virus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004638 Circular DNA Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101710150114 Protein rep Proteins 0.000 description 2
- 101710152114 Replication protein Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 210000001099 axilla Anatomy 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 208000028489 postweaning multisystemic wasting syndrome Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001533399 Circoviridae Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 210000001739 intranuclear inclusion body Anatomy 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000004262 preparative liquid chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
名称 | Pigpsa-PCV2cap2 |
猪血清片段片段 | 1-607 |
链接肽 | 608-622 |
Cap2 | 623-860 |
分组 | 设计 | 融合疫苗中蛋白含量 |
单剂量一次免疫组 | 按颈部肌肉注射接种2ml疫苗 | 100μg融合蛋白含量/头 |
单剂量2次重复免 | 在单剂量组接种2周后以相同方法剂量再接种一次 | 100μg融合蛋白含量/头 |
超剂量一次免疫组 | 按颈部肌肉注射接种2ml疫苗 | 500μg融合蛋白含量/头 |
对照组 | 直接注射生理盐水 | 0μg融合蛋白含量/头 |
分组 | 头数 |
佐剂A Pigpsa-PCV2cap25μg/ml | 5 |
佐剂A Pigpsa-PCV2cap2 50μg/ml | 5 |
佐剂B Pigpsa-PCV2cap25μg/ml | 5 |
佐剂B Pigpsa-PCV2cap2 50μg/ml | 5 |
疫苗组 | 5 |
对照组 | 5 |
阴性对照 | 5 |
实验内容 | 取样和检测 |
免疫组首次免疫 | 采血5~10ml/头,分离血清;首免。 |
免后7天采血 | 免疫对照组采血5~10ml/头,分离血清,测抗体。 |
免后14天采血 | 免疫对照组采血5~10ml/头,分离血清,测抗体。 |
免后21天采血 | 免疫对照组采血5~10ml/头,分离血清,测抗体。 |
28天攻毒 | PCV2 DN株(106.0TCID50 /ml)滴鼻1 m1、肌肉注射2ml |
观察25天 | 4、7日,分别在每头猪两侧腋下及两侧臀部共4个点对所有猪接种用弗氏不完全佐剂乳化的钥匙孔血蓝蛋白 (KLH/ICFA,0.5mg/ml),每个点接种 lml (4ml/头),同时腹腔接种巯基乙酸培养基,10 ml/头;攻毒后第11、19日再次分别腹腔接种巯基乙酸培养基, |
屠宰剖检 | 称重,剖检观察病变。 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710603507.XA CN107325188B (zh) | 2017-07-23 | 2017-07-23 | 猪血清蛋白融合猪圆环病毒Cap2蛋白的CHO细胞株的构建方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710603507.XA CN107325188B (zh) | 2017-07-23 | 2017-07-23 | 猪血清蛋白融合猪圆环病毒Cap2蛋白的CHO细胞株的构建方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107325188A CN107325188A (zh) | 2017-11-07 |
CN107325188B true CN107325188B (zh) | 2022-08-23 |
Family
ID=60199787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710603507.XA Active CN107325188B (zh) | 2017-07-23 | 2017-07-23 | 猪血清蛋白融合猪圆环病毒Cap2蛋白的CHO细胞株的构建方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107325188B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110747215A (zh) * | 2019-11-01 | 2020-02-04 | 北京鼎持生物技术有限公司 | 一种高效表达猪瘟e2蛋白的重组杆状病毒及其构建方法 |
CN114230677B (zh) * | 2022-02-23 | 2022-05-10 | 北京中海生物科技有限公司 | 含有猪瘟E2和圆环病毒的Cap的重组蛋白及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009000459A1 (en) * | 2007-06-22 | 2008-12-31 | Ghent University | Methods and compositions in the treatment of porcine circoviral infection |
CN105992770A (zh) * | 2013-11-01 | 2016-10-05 | 奥斯陆大学 | 白蛋白的变体及其用途 |
CN106519041A (zh) * | 2016-11-24 | 2017-03-22 | 唐山怡安生物工程有限公司 | 猪免疫球蛋白Fc片段和猪瘟E2融合蛋白在CHO细胞株的构建方法及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2564869A1 (en) * | 2011-09-02 | 2013-03-06 | Ceva Sante Animale | Synthetic capsid proteins and uses thereof |
-
2017
- 2017-07-23 CN CN201710603507.XA patent/CN107325188B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009000459A1 (en) * | 2007-06-22 | 2008-12-31 | Ghent University | Methods and compositions in the treatment of porcine circoviral infection |
CN105992770A (zh) * | 2013-11-01 | 2016-10-05 | 奥斯陆大学 | 白蛋白的变体及其用途 |
CN106519041A (zh) * | 2016-11-24 | 2017-03-22 | 唐山怡安生物工程有限公司 | 猪免疫球蛋白Fc片段和猪瘟E2融合蛋白在CHO细胞株的构建方法及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
,cap protein [Porcine circovirus 2;Accession No.: AAO24125;《Genbank》;20090910;参见ORIGIN部分 * |
猪圆环病毒2型Cap蛋白表达及免疫原性鉴定;朱鹏等;《中国动物传染病学报》;20141231;第22卷(第5期);第28-34页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107325188A (zh) | 2017-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110606873B (zh) | 猪圆环病毒2d型与3型Cap蛋白二联亚单位疫苗及其制备方法与应用 | |
CN113058032B (zh) | 一种猪瘟、猪伪狂犬病和猪圆环病毒2型三联亚单位疫苗及其制备方法和应用 | |
CN110358742B (zh) | 猪圆环病毒2b型和2d型的二价亚单位疫苗及其制备方法 | |
CN102333876A (zh) | 基于pcv 2的用于治疗猪的方法和组合物 | |
CN111558037A (zh) | 一种二价亚单位疫苗及其制备方法和应用 | |
CN106399350A (zh) | 一种猪圆环病毒ii型病毒样颗粒疫苗及其制备方法 | |
CN113355287A (zh) | 一种猪圆环病毒2型及3型二价疫苗及其制备方法 | |
CN107973841B (zh) | Cho细胞表达的重组牛病毒性腹泻病毒e2蛋白及亚单位疫苗的制备方法和应用 | |
CN112142851A (zh) | 一种狂犬病毒表面的亚单位融合蛋白tG及其制备方法和应用 | |
CN107325188B (zh) | 猪血清蛋白融合猪圆环病毒Cap2蛋白的CHO细胞株的构建方法及其应用 | |
JP7387623B2 (ja) | 標的タンパク質を安定して発現できる組換えウイルス | |
CN114222579A (zh) | 猪圆环病毒3型(pcv3)疫苗及其生产和用途 | |
CN114107229A (zh) | 猪圆环病毒2b型和2d型的二价亚单位疫苗及其制备方法 | |
EP3399040A1 (en) | Method of preparing porcine circovirus type 2 capsid protein and pharmaceutical composition comprising same | |
WO2023207717A1 (zh) | H5n8禽流感广谱性疫苗的开发及其应用 | |
CN110305225B (zh) | Sva-pcv2融合蛋白及其制备方法、基因、生物材料、应用和疫苗 | |
CN115073565A (zh) | 重组新型冠状病毒s蛋白三聚体及其制备方法与应用 | |
CN112679616B (zh) | 一种牙鲆弹状病毒基因工程亚单位疫苗 | |
CN114107176A (zh) | 一种稳定表达非洲猪瘟CD2v蛋白的CHO细胞系及其构建方法和应用 | |
CN114058524A (zh) | 一种法氏囊亚病毒颗粒疫苗及其制备方法 | |
CN114395052B (zh) | 一种重组禽流感三价疫苗及其制备方法与应用 | |
CN115960265B (zh) | 一种长效多价猪口蹄疫和猪瘟疫苗及其制备方法和应用 | |
CN116904489B (zh) | 一种鸭坦布苏病毒核酸疫苗及应用 | |
CN108610424A (zh) | 一种重组蛋白及其在制备猪圆环病毒和猪繁殖与呼吸综合征病毒疫苗中的应用 | |
CN109810983B (zh) | 猪IFN-γ的优化基因和采用该优化基因制备猪IFN-γ的方法及其注射液和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240423 Address after: 063000 Torch Road, Tangshan City hi tech Development Zone, Hebei 120, China Patentee after: Tangshan Yi'an Biological Engineering Co.,Ltd. Country or region after: China Address before: 120 Huoju Road, Lubei District, Tangshan City, Hebei Province Patentee before: Tangshan Yi'an Biological Engineering Co.,Ltd. Country or region before: China Patentee before: BEIJING JIAHUA DAIWEI BIOTECHNOLOGY Co.,Ltd. |